Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like Biogen Forges $278M MS Tie-Up With Alkermes November 26, 2017 Innocoll Announcement Relating To The Outcome Of The Court Sanction Hearing July 20, 2017 Are Life Science Companies Falling Behind Tech Companies? March 12, 2018